Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors

Cytotechnology

Volumn 41, Issue 2-3, 2003, Pages 197-206

  Carvallo, Cristian ^a   Childs, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allogeneic transplant; Graft versus tumor; Immunotherapy; Nonmyeloablative stem cell transplant; Renal Cell Carcinoma

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; THYMOCYTE ANTIBODY;

ADULT; BREAST CANCER; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; HUMAN CELL; KIDNEY CANCER; LEUKEMIA; MAJOR CLINICAL STUDY; MELANOMA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVARY CANCER; SOLID TUMOR; STEM CELL TRANSPLANTATION;

EID: 0042382896     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024839225920     Document Type: Conference Paper

References (67)

1. Anderson Jr, LD, Mori S, Mann S & Savary CA (2000) Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res 60: 5797-5802.
2. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411: 385-389.
3. Asai O, Longo DL, Tian Z, Hornung RL, Taub DD, Ruscetti FW & Murphy WJ (1998) Suppression of graft-versus-host disease and amplification of graft-versus-tumor effect by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 101: 1835-1842.
4. Barnes DWH, Corp MJ, Loufit JF & Neal FE (1956) Treatment of murine leukaemia with X-Rays and homologous bone marrow: Preliminary communication. Br Med J 2: 626-627.
5. Barrett AJ (1997) Mechanisms of Graft-versus-Leukemia Reaction. Stem Cell 15: 248-258.
6. Beguin Y, Collignon J, Laurent C & Fillet G (1996) Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. Br J Haematol 94: 507-509.
7. Ben-Yosef R, Or R, Nagler A & Slavin S (1996) Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348: 1242-1243.
8. Baron F & Beguin Y (2000) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 40: 468-476.
9. Bay JO, Choufi B, Pomel C, Dauplat J, Durando X, Tournilhac O, Travade P, Plagne R & Blaise D (2000) Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant 25: 681-682.
10. Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C & Blaise D (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: Results of five patients. Bone Marrow Transplant 30: 95-102.
11. Blaise DP, Bay JO, Michallet M, Boiron JM, Cahn JY, Ifrah N, Sotto JJ, Gratecos N, Faucher C, Blay JY, Olive D, Maraninchi D & Viens P (2002) A feasibility study of allogeneic immunotherapy for solid tumors. Proc A Soc Clin Oncol, A1664.
12. Bornhauser M, Haenel M, Platzbecker U, Roellig C, Waessa T, Schmidt H, Ehninger G & Kroschinsky F (2002) Graft-versus-tumor effects after reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation for ovarian cancer. Proc A Soc Clin Oncol: A2954.
13. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C & Corradini P (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99: 4234-4236.
14. Bregni M, Peccatori J, Dodero A, Bernardi M, Corti C, Pescarollo A, Ciceri F, Bordignon C & Corradini P (2002) Clinical responses to reduced-intensity allogeneic stem cell transplantation in solid tumors: Strong association with graft-versus-host disease. Proc A Soc Clin Oncol, A1665.
15. Champlin R, Khouri I, Shimoni A, et al. (2000) Harnessing graft-versus malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111: 18-29.
16. Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS & Barrett AJ (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94: 3234-3241.
17. Childs R, Bradstock KF, Gottlieb D, et al. (2000a) Nonmyeloablative stem cell transplantation as immunotherapy for metastatic melanoma: Results of a pilot study. Blood 96: A3536.
18. Childs R, Chernoff A, Contenin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS & Barrett AJ (2000b) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343: 750-758.
19. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gächter A, Knapp R, Böck G, Gassner C, Schiller L, Petersen F & Niederweiser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88: 1501-1508.
20. Fefer A, Sullivan KM, Weiden P, et al. (1987) Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. In RL Truitt, RP Gale & MM Bortin (Eds.) Cellular Immunotherapy of Cancer. Alan R Liss, New York, pp. 401-408.
21. Gale RP & Horwitz MM (1990) Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant Registry. Bone Marrow Transplant 6(1): 94-97.
22. Gambacorti-Passerini C, Bertazzoli C, Dermime S, Scardino A, Schendel D & Parmiani G (1997) Mapping of HLA class I bindings motifs in forty-four fusion proteins involved in human cancers. Clin Cancer Res 3: 675-683.
23. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippoliti C, Claxton DF, Donato M, Bruton J, Cohen A, Davis M, Andersson B, Anderlini P, Gajewski J, Komblau S, Andreef M, Przepiorka D, Ueno NT, Molldrem J & Champlin R (2001) Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97: 631-637.
24. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin R, Gluckman E, Hoffman M, Jacobsen N, Marmont AM & McGlave P (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 108: 806-811.
25. Goulmy E (1997) Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157: 125-140.
26. Horowitz MM, Gale RP, Sondel PM, et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
27. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ (1993) T cell and NK cell mediated graft versus leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 11: 133-138.
28. Junghanss C, Marr K, Carter R, Sandmeier B, Maris M, Maloney D, Chauncey T, McSweeney P & Storb R (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol of Blood and Marrow Trans 8: 512-520.
29. Kolb HJ, Mittermuller J, Clemm C, Lederose G, Brehm G, Heim M & Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465.
30. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L & Niederweiser D (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 86: 2041-2050.
31. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH & Mackinnon S (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96: 2419-2425.
32. Lamb Jr LS, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C & Gee AP (1996) Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother 5: 503-509.
33. Lee M, Champlin R, Kantarjian H & Stass S (1992) Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukemia following allogeneic bone marrow transplantation. Br J Haematol 82: 708-714.
34. Mattei D, Saglio G, Gottardi E, Gallamini A, Mordini N & Bacigalupo A (2001) Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 86: 545-546.
35. McSweeney PA, Niederweiser D, Shizuru J, Sandmaier BM, Molina A, Maloney DG, Chauncey TR, Gooley T, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryan E, Flowers ED, Georges G, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG & Storb R (2001) Hematopoietic cell transplantation in older patients with hematological malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97: 3390-3400.
36. Mehta J, Powles R, Kulkarni S, Treleaven J & Singhal S (1997) Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adult patients. Bone Marrow Transplant 20: 129-135.
37. Melioli G, Guastella M, Semino C, Meta M, Pietra G, Ponte M, Queirolo P, Sertoli MR, Martini L & Reali UM (1994) Proliferative, phenotypic and functional and molecular characteristics of tumor-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2. Melanoma Res 4: 127-133.
38. Morecki S, Gelfand Y, Levi S, Nagler A, Condiotti R, Nabet C, Ackerstein A & Slavin S (1997) Activated long-term peripheral blood cultures as preparation for adoptive alloreactive therapy in cancer patients. J Hematother 6: 115-124.
39. Morecki S & Slavin S (2000) Toward amplification of a graft-versus-leukemia effect While minimizing graft-versus-host disease. J Hematother Stem Cell Res 9: 355-366.
40. Moscardo F, Martinez JA, Sanz G, Jimenez C, Cervera J, Sanchis J, Vera FJ & Sanz MA (2000) Graft-versus-tumour effect in non-small-cell lung cancer after peripheral blood stem cell transplantation. Br J of Haemat 111: 708-710.
41. Moscovitch M & Slavin S (1984) Antitumor effects of allogeneic bone marrow transplantation in (NZB X NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 132: 997-1003.
42. Motzer RJ & Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408-417.
43. Ohminami H, Yasukawa M & Fujita S (2000) HLA class-I restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT-1 peptide. Blood 95: 286-293.
44. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K & Sugiyama H (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT-1) product. Immunogenetics 51: 99-107.
45. Pedrazzoli P, Giorgiani G, Schiavo R, Renga M, Sironi O, Locatelli F & Siena S (2002a) Allogeneic hematopoietic stem cell transplantation (alloHSCT) following reduced-intensity chemotherapy for sarcoma. Proc A Soc Clin Oncol: A2949.
46. Pedrazzolli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S & Della Cuna GR (2002b) Allogeneic blood stem transplantation after a reduced-intensity, preparative regimen. Cancer 94: 2409-2415.
47. Rini B, Zimmerman T, Galewski T, Stadler W & Vogelsang N (2001) Allogeneic peripheral blood stem transplantation for metastatic renal cell carcinoma. J of Urol 165: 1208-1209.
48. Rini B, Zimmerman T, Stadler W, Gajewski T & Vogelzang J (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Oncol 20: 2017-2024.
49. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH & White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin-2. JAMA 271: 903-913.
50. Ruggeri L, Capanni M, Casucci M, Volpi I, Toski A, Perruccio K, Urbani E, Negrin RS, Martelli MF & Velardi A (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
51. Ruggeri L, Capanni M, Urbani E, Perruccio K, Schlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF & Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562): 2097-2100.
52. Sandmaier B, Masood N, Thompson J & Storb R (2002) Fludarabine and total body irradiation (TBI), followed by allogeneic hematopoietic stem cell transplant (HSCT) as immunotherapy for metastatic renal cell carcinoma (MRCC) Proc A Soc Clin Oncol, A1677.
53. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A & Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763.
54. Slavin S, Or R, Prighozina T, Gurevich O, Aker M, Panighari S, Shapira M & Nagler A (2000) Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Bone Marrow Transplantation 25(2): S54-S57.
55. Spitzer TR, McAfee S, Sackstein R, et al. (2000) Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 6: 309-320.
56. Sullivan KM, Weiden PL, Storb R, et al. (1989a) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73: 1720-1728.
57. Sullivan KM, Storb R, Buckner CD, et al. (1989b) Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320: 828-834.
58. Suzuki R, Taji H, Iida S, Miura K, Kagami Y, Ogura M, Yatabe Y, Nakamura S, Seto M & Morishima Y (1997) Complete cytogenetic response with host-derived hematopoiesis induced by cyclosporin A discontinuation in a patient with relapsed chronic myelogenous leukemia after bone marrow transplantation. Bone Marrow Transplant 20: 615-617.
59. Teshima T, Liu C, Lowler K, Dranoff G & Ferrara JLM (2002) Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res 62: 796-800.
60. Thomas ED, Storb R, Clift RA, et al. (1975) Bone-marrow transplantation. N Engl J Med 292: 832-843, 895-902.
61. Truitt RL & Atasoylu AA (1991) Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8: 51-58.
62. Ueno N, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt S, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, Van Besien K, Hortobagyi GN & Champlin RE (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16: 986-993.
63. Warren EH, Greenberg PD & Riddell SR (1998a) Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91: 2197-2207.
64. Warren EH, Gavin M, Greenberg PD & Riddell SR (1998b) Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol 5: 429-433.
65. Weiden PL, Flournoy N, Thomas ED, et al. (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068-1073.
66. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, the Seattle Marrow Transplant Team (1981) Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529-1533.
67. Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M & Rosenberg SA (1996) Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 65: 413-421.